RE: Don’t add up1 Feb 2025 09:22
Having read the TU update again my concern with he product and sales potential dont match the beaten up share price.
They had 9 million in revenue minus the milestone payment and expect 18 million for 2025 based on prudent forecasts.
It was worded horrendously, talking down expectations like that is pointless especially when early indications in the USA look promising.
On reviews.........
Speaking from experience. I am a 40s male. Very fit for my age and have no problems getting an erection. It takes me a little longer to recover and repeat (maybe 30 minutes these days) so I have no need for any medical assistance or Erexon.
In my 30s I came into possession of a few Viagra tablets. I took one out of curiosity on a "match" free day. So no action just purely to see what happened. Well nothing happened.
When the time came to use it with a partner it was a different kettle of fish all togeather. It needed to be used with a partner.
Now if Erexon is the same it makes total sense that there are so many bad reviews, especially when the trials say its only really efffective on 60% of men or whatever.
If they are expecting revenue of 18 million for 2025 then there must be faith in repeat sales. Its been on sale in the UK for sometime, Enough to see if sales have fallen off a cliff after a bunch of reviews of creeps using it on their own to beast themselves watching Only Fans.
I will continue to hold. I only have a small holding compared to most but still annoying.